Pfizer spells out PhIII talazoparib data in NEJM article; Tolero teams up with AbbVie for AML combo
→ David Hung offered a hard sell of his experimental PARP drug talazoparib while bidders lined up in what turned out as a $14 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
